Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Rein Therapeutics (RNTX): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow RNTX for free
Share

Sections with a free account

5 concentrated managers hold it (+1 vs last quarter); combined they have held more shares for 9 quarters in a row (3 added, 1 trimmed). Its median weight in those portfolios is 0.2%. 2 officers or directors bought in 6 months.

Who owns Rein Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Bios Capital Management, 10.0% (13G/A filed May 8, 2026), Funicular Funds, 6.7% (13G filed May 7, 2026), Voss Capital, 6.6% (13G/A filed Jul 14, 2026), Bios Equity Partners III, 6.2% (13G filed Aug 11, 2025) and ADAR1 Capital Management, 5.3% (13G filed Aug 14, 2026). Voss Value Master Fund, LP and Voss Value-Oriented Special Situations Fund, LP are listed on their Form 4 filings as owners of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Voss Capital (6.2% of the shares), Cable Car Capital (6.1%) and ADAR1 Capital Management (5.3%).

Which institutions hold the most Rein Therapeutics shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. Voss Capital: 6.2%
  2. 2. Cable Car Capital: 6.1%
  3. 3. ADAR1 Capital Management: 5.3%
  4. 4. Vanguard Capital Management: 3.9%
  5. 5. BIOS Capital Management: 3.5%
  6. 6. Ikarian Capital: 3.4%
  7. 7. Great Point Partners: 3.0%
  8. 8. Citadel Advisors: 2.9%
  9. 9. Velan Capital Investment Management: 2.0%
  10. 10. Senvest Management: 1.4%

How much of Rein Therapeutics do institutions own?

The 57 institutions that file 13F reported 47.5% of the shares as of Jun 30, 2026.

Sources:13G/A by Bios Capital Management (May 8, 2026) ↗13G by Funicular Funds (May 7, 2026) ↗13G/A by Voss Capital (Jul 14, 2026) ↗13G by Bios Equity Partners III (Aug 11, 2025) ↗13G by ADAR1 Capital Management (Aug 14, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 13, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
5
All 13F: 57
Consensus
54/100
across 5 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$1.04
-20.0% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (4 → 5): 1 opened · 0 exited = +1

Net flow in the quarter: +$5.3M (+5.1 M shares) · bought $5.3M and sold $11KShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Accumulation: combined they have held more shares for 9 quarters in a row (3 added, 1 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of RNTX (all 13F filers)

  • Voss Capitalconcentrated5.3 MInvestment firm · 6.10% of the company+874 K
  • Cable Car Capital5.2 MType not verified · 6.02% of the company+4.8 M
  • ADAR1 Capital Management4.5 MType not verified · 5.22% of the company+4.5 M
  • Vanguard Capital Management3.4 MIndex manager · 3.92% of the company+2.4 M
  • BIOS Capital Management3.0 MType not verified · 3.46% of the company+1.0 M
  • Ikarian Capital3.0 MType not verified · 3.42% of the company+3.0 M
  • Great Point Partnersconcentrated2.6 MType not verified · 2.98% of the company+2.6 M
  • Citadel Advisors2.4 MQuant or multi-manager · 2.83% of the company+2.4 M
  • Velan Capital Investment Management1.7 MType not verified · 1.97% of the company+1.7 M
  • Senvest Managementconcentrated1.2 MInvestment firm · 1.43% of the company+1.0 M

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 47.5% of the shares · top 10: 37.7% · in index firms: 13.2% of the institutional total

Share of the stock held by 13F filers

Q2 2026: 47.5%

47.5%1.5%
Q4 2022Q2 2026

Shares reported by the 57 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 13, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
-90.1%
Growth
Revenue (TTM)
$0
Revenue growth
—
Net income (TTM)
$-49.8M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
—
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 25.4 M

25.4 M0
20212025

There is a jump that may be an undetected split: we do not show the changes.

Buybacks (FY 2025)
no data
Share issuance
$1.8M
Stock-based compensation
$2.2M
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
no data
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
2
Amount (6 m)
$74.7K
CEO/CFO bought (12 m)
Yes

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • ADAR1 Capital Management5.3%13Gfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026
  • Lynwood Capital Management5%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026
  • Lytton Laurence W4.9%(fell below 5%)13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 13, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Aug 27, 2026Seriousfiling ↗

    Notice of delisting or failure to meet a listing rule (Item 3.01)

  • Mar 2, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • Feb 19, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Jan 16, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow RNTX for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow RNTX